RASPADORI, DONATELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.570
EU - Europa 1.276
AS - Asia 162
AF - Africa 4
OC - Oceania 3
SA - Sud America 2
Totale 3.017
Nazione #
US - Stati Uniti d'America 1.567
GB - Regno Unito 347
IE - Irlanda 345
SE - Svezia 193
CN - Cina 123
IT - Italia 120
UA - Ucraina 94
FR - Francia 64
DE - Germania 37
BE - Belgio 33
FI - Finlandia 30
TR - Turchia 16
VN - Vietnam 13
EG - Egitto 4
AU - Australia 3
IN - India 3
IR - Iran 3
ES - Italia 2
GR - Grecia 2
MX - Messico 2
NL - Olanda 2
PH - Filippine 2
RU - Federazione Russa 2
CA - Canada 1
CL - Cile 1
CZ - Repubblica Ceca 1
GE - Georgia 1
HK - Hong Kong 1
LU - Lussemburgo 1
MK - Macedonia 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.017
Città #
Dublin 344
Southend 322
Fairfield 275
Chandler 155
Ashburn 154
Woodbridge 113
Seattle 111
Houston 97
Wilmington 92
Cambridge 80
Ann Arbor 79
Jacksonville 77
Siena 47
Princeton 46
Brussels 33
Beijing 30
Helsinki 23
San Mateo 22
Nanjing 21
San Diego 18
Dearborn 15
Izmir 15
Boardman 14
Shanghai 14
Dong Ket 12
New York 12
Menlo Park 10
Rome 9
Shenyang 9
Nanchang 8
London 7
Washington 7
Jinan 6
San Francisco 6
Florence 5
Cairo 4
Changsha 4
Hebei 4
Jiaxing 4
Andover 3
Gussago 3
Ningbo 3
Norwalk 3
Tianjin 3
Atlanta 2
Bologna 2
Canberra 2
Chiampo 2
Chiswick 2
Düsseldorf 2
Frankfurt am Main 2
Fremont 2
Guangzhou 2
Haikou 2
Hefei 2
Henderson 2
Hounslow 2
Lancaster 2
Leawood 2
Milan 2
Málaga 2
Pisa 2
Redwood City 2
Reggio Emilia 2
San Giuliano Terme 2
Turin 2
Zanjan 2
Zhengzhou 2
Albignasego 1
Almere Stad 1
Ascoli Piceno 1
Auburn Hills 1
Birmingham 1
Bolzano 1
Borås 1
Bratislava 1
Castellammare Di Stabia 1
Chongqing 1
Delhi 1
Des Moines 1
Falkenstein 1
Greve in Chianti 1
Hangzhou 1
Kilburn 1
Kocaeli 1
Kunming 1
Lanzhou 1
Lappeenranta 1
Lima 1
Luxembourg 1
Manila 1
Markham 1
Melbourne 1
Modena 1
Montevarchi 1
Mumbai 1
Nashville 1
New Bedfont 1
Parma 1
Phoenix 1
Totale 2.399
Nome #
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 190
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 189
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 171
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 156
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 156
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 155
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 140
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 139
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 138
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 118
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 115
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 110
An unusual presentation of chronic B-cell lymphocytic leukaemia 109
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 98
Selection and Transplantation of Autologous Hematopoietic CD34+ Cells for Patients with Multiple Myeloma 97
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 85
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 84
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 78
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 75
Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia 74
Anti CD38 monoclonal antibodies for multiple myeloma treatment 70
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 69
Trisomy 8 in chronic lymphocytic leukemia: a report of two cases 65
Relationship between immunological response to alpha-IFN treatment in 35 patients with hairy cell leukemia 59
Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma 55
Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma 54
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia 49
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 45
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 36
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 26
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 24
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 21
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy 17
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 16
“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow 13
Tp53 disruptions: Is there a marker of poor prognosis in chronic lymphoproliferative disorders? 6
Totale 3.102
Categoria #
all - tutte 11.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.047


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019248 0 0 0 0 0 0 0 0 14 41 106 87
2019/2020624 86 25 30 90 43 52 55 72 61 61 17 32
2020/2021565 22 37 47 69 33 54 42 80 32 65 39 45
2021/2022387 26 28 30 69 20 16 12 10 15 41 45 75
2022/2023599 33 61 81 74 53 107 15 73 53 14 29 6
2023/2024509 14 15 59 47 28 142 198 6 0 0 0 0
Totale 3.102